Share

Quotes

This marks an important step in the ABY-025 program as we are now demonstrating use in gastroesophageal cancer. We appreciate for our close collaboration with the leading clinical experts at Karolinska Institutet and Karolinska University Hospital and believe that the study results will pave the way for our therapeutic candidate ABY-271 in this patient population.
Fredrik Frejd, Professor and Chief Scientific Officer of Affibody
68Ga-ABY-025 has demonstrated the ability to visualize HER2 metastases with low-HER2 expression in our recently published study of metastatic breast cancer patients. I am excited about the opportunity to investigate this further in additional patients.
Rimma Axelsson, Professor of Nuclear Medicine and Principal Investigator (PI) of the study
“Patients with gastroesophageal cancer may have a high degree of variability of HER2 expression level in different tumor lesions. It is important to understand HER2 receptor status in this patient population to guide the use of HER2 targeted treatment.
Magnus Nilsson, Professor of Surgery and deputy PI in the study
Dr. Uwe Gottschalk's appointment as new Chairman marks a major milestone for Cellevate. With his extensive industry knowledge, decades of experience, and invaluable network connections, Dr. Uwe Gottschalk is well-suited to lead Cellevate into its next phase of growth and commercialization. I am confident that under Dr. Gottschalk's guidance, Cellevate will continue to thrive and achieve new heights of success.
Mats Leifland, the departing Chairman of Cellevate's Board
I am thrilled to be Joining Cellevate as the new Chairman and to become part of such a dynamic and innovative company. I am looking forward to working with the Board of Directors and the Cellevate team to contribute to successful launch and commercialization of our unique nanotechnology in the field of bioprocessing.
Dr. Gottschalk.
The clinical decision support tool evaluated in this investigation showed high diagnostic accuracy when used prospectively on primary care patients, which could add significant clinical value for PCPs in assessing skin lesions to detect melanoma. Additionally, a further clear impression from this trial is that the medical personnel involved in the trial were willing to put a high level of trust in Dermalyser, strongly indicating it can be easily worked into current clinical routines.
Magnus Falk, Associate Professor in General Practice and Principal Investigator, Department of Health, Medicine and Caring Sciences, Linköping University
In recent years, the precision of AI in analysing dermatoscopic images to identify melanoma has reached or even surpassed experienced dermatologists. Yet, only a limited number of studies have tested these systems under real-world conditions. This study is notable for its execution in a real clinical setting, which makes its findings especially compelling. I am enthusiastic about the results and anticipate being a part of a future where systems like Dermalyser, supported by rigorous research and in full compliance with all necessary regulations, are integrated into routine healthcare. This includes both general dermatology and specifically the diagnosis of skin cancer. The fundamental goal is, of course, to improve clinical decision-making processes for more precise and, therefore, safer diagnoses.
Sam Polesie, Adjunct Senior Lecturer, Department of Dermatology and Venereology, Sahlgrenska University Hospital, Gothenburg
Just as in analysing mammograms for diagnosing breast cancer or neuroimaging for Alzheimer’s disease, we believe this trial has decisively proven that using AI can revolutionise melanoma diagnosis. This will save lives and also remove the anxiety and often devasting consequences of false results. The European market is still our first priority for Dermalyser, but the recently approved AI-powered device for detecting skin cancer by the FDA has also established a clear regulatory pathway for us and we are now accelerating our plans for entering the US market.
Christoffer Ekström, CEO of AI Medical Technology
We are pleased that the Swedish Medical Products Agency has given the go-ahead for the start of our clinical study with ELC-301 in difficult-to-treat or recurrent B-cell lymphoma. The treatment has the potential to become a very important alternative for those patients whose disease no longer respond to standard therapy and thus lack effective treatment options. The study is also an important step in proving the enhancing function of our technology platform iTANK, which has the potential to activate the body's own immune system against cancer cells.
Jamal El-Mosleh, CEO of Elicera Therapeutics.
We are very excited to partner with the expert team at Offspring. With their vast experience developing innovative biomarker and assay solutions, we are very confident that our combined offerings will bring a unique and valuable combination of translational and clinical capabilities to our development partners.
Flagship Biosciences CEO Trevor Johnson
Together, Flagship Biosciences and Offspring Biosciences will provide a seamless and comprehensive suite of preclinical and clinical services, empowering our clients to accelerate drug development and bring lifesaving therapies to patients faster.
Anders Dahlstrand, CEO of Offspring Biosciences.
We are delighted to welcome Dr. Chiò to join our SAB. With his vast experience and expertise spanning from the phenotypic heterogeneity of ALS to familial ALS, his advice will be of great importance as we advance our clinical program for the drug candidate ILB for treatment of ALS.
Adam Bruce, Founder, Chairman of the Board and CEO, of TikoMed
Understanding the phenotypic heterogeneity and identifying the causative genetic mutations is key to developing new treatments for ALS, and I look forward to contributing the knowledge gained by my various research teams in this area and ALS in general to TikoMed’s SAB.
Professor Adriano Chiò, of the University of Torino and the Città della Salute e della Scienza Hospital
We are thrilled to welcome Dr. Shefner to join our SAB. We are confident that his expertise within biomarker development for ALS diagnosis and experience from the NEALS consortium will be of great value for progressing our drug candidate ILB for treatment of ALS through the clinical program.
Adam Bruce, Founder, Chairman of the Board and CEO, of TikoMed.
I am pleased to join the TikoMed Scientific Advisory Board, and look forward to assisting the company in reaching the next stage of clinical development. The company has an ambitious plan to design and implement a study with solid and reliable readouts to ensure accurate assessment of their experimental therapeutic agent.
Professor Jeremy Shefner, MD, PhD
We are thrilled to have gained tremendous support from such a strong syndicate of investors, who share our vision of transforming biomanufacturing. This investment represents a significant milestone for our company and a valuable endorsement for the potential of our Cellevat3d™ nanotechnology, allowing us to take the next pivotal steps on our journey. The financing will enable us to accelerate commercialization and to progress towards our goal of making a lasting impact in the global healthcare landscape.
Laura Chirica, PhD, CEO Cellevate
We are impressed by Cellevate's groundbreaking technology and the team behind it. This investment reflects our commitment to supporting pioneering companies that have the potential to revolutionize the industry. We look forward to a long-term partnership with Cellevate as they advance their mission of driving innovation in biomanufacturing.
Mala Valroy, Investment Manager at Industrifonden and incoming board member of Cellevate
As cell culture and biomanufacturing processes do play an increasingly important role, we are looking for start-ups like Cellevate that have the potential to set new industry standards.
Herman Hauser, PhD, serial entrepreneur, Venture Partner, and advisor at Onsight Ventures
The EIC Fund has established itself as a strong force in EU deep-tech investments. This unique form of financing via EIC - combining grants and equity – is proving itself highly attractive to Europe's most promising start-ups. Our investment will provide Cellevate with means to scale up their nanotechnology and accelerate their global commercial launch.
Svetoslava Georgieva, Chair of the EIC Fund Board
Since joining Affibody, I have been thoroughly impressed with my colleagues’ expertise and the potential of the product pipeline. I am excited to contribute to our strategic growth initiatives and taking the Company to the next level.
Peter Zerhouni, CFO and CBO of Affibody
The preliminary results are promising and open up a new therapeutic opportunity for patients with severe CVI.
TECVI-1 Principal Investigator Dr Andrés Garcia
We are presenting this news because we believe the progress so far demonstrates our key premise – that our P-TEV grafts offer a solution to the problem with transplantation of vascular grafts. It follows the recent one-year disease-free milestone reached by our first patients. We now look forward to completing TECVI-1 and advancing the other programs in our pipeline including arteries.
VERIGRAFT CEO Petter Björquist
We are excited to welcome Dr. Ingre to join our SAB. Caroline is a world renowned clinical and scientific thought leader. We look forward to her providing TikoMed with informed counsel in the months and years ahead, as we further our clinical efforts with our drug candidate ILB for treatment of ALS.
Adam Bruce, Founder, Chairman of the Board and CEO, of TikoMed.
I am delighted to join TikoMed’s SAB at this exciting time for both ALS research in general and ILB in particular. I hope my extensive clinical development and trials experience can be utilized to the benefit of patients suffering from this devasting disease.
Associate Professor and Research Group Leader, ALS
We are excited to welcome Dr. Cudkowicz to join our SAB. Merit, is a world renowned clinical and scientific thought leader. She can provide TikoMed with relevant and informed counsel in the months and years ahead, as we further our clinical efforts.
Adam Bruce, Founder, Chairman of the Board and CEO, of TikoMed
I feel very enthusiastic about joining the TikoMed SAB and I looking forward to contributing my experience to the upcoming clinical study.
Dr Merit Cudkowicz
“Although the overall study did not meet statistical significance, as reported by our partner ACELYRIN, izokibep appears to be demonstrating high orders of response for patients suffering from hidradenitis suppurativa without safety or tolerability limitations. The consistent and early achievement of HiSCR100, along with the prior izokibep experience in Psoriatic Arthritis (PsA), continues to demonstrate the potential of izokibep for resolution of disease, especially in difficult to treat tissues. Our partner continues to evaluate izokibep in additional ongoing late-stage trials in HS, PsA, and uveitis, with top-line data for the Phase 2b/3 trial in PsA expected in Q1, 2024.”
David Bejker, CEO of Affibody
The results from this important study strongly indicate that the impact of Sigrid’s SiPore® technology on glucose homeostasis shown in our previous studies in animals and man is not due to altered enzyme activity. In contrast, the findings are compatible with a mode of action by which orally ingested MSPs exclusively act as “molecular sieves”, physically preventing digestive enzymes from interacting with food and consequently reducing the breakdown of carbohydrates and fats. Therefore, the study provides further support for our case to classify Sigrid’s SiPore® formulations as medical devices, not pharmaceuticals.
Professor Tore Bengtsson (Stockholm University), Sigrid Co-founder and CSO
This data bolsters the understanding of SiPore21®'s mechanical mode of action and reinforces its medical device classification”, says Sana Alajmovic, Co-founder & CEO, Sigrid Therapeutics. “We are excited about the prospect of obtaining approval for SiPore21® as the world's first oral medical device dedicated to blood sugar control in prediabetics.
Sana Alajmovic, Co-founder & CEO, Sigrid Therapeutics
This certification is a fundamental step in our pursuit of the use of GAGomes to guide critical medical decisions in cancer. It is an enabler for potential future clinical use of the tests we are developing,
Karl Bergman, CEO at Elypta
We are proud of receiving this certification and being able to send a clear message that quality matters in everything we do at Elypta. Quality management involves everyone at the company and this certification is a collective achievement by the entire team.
Dilruba Ahmed, Director of Quality & Regulatory Affairs at Elypta.
AI Medical Technology has developed a unique and patented product that addresses a huge market. It creates value and benefit for people, healthcare and society at large. Through AI, the company has truly created an aid that is scalable and applicable all over the world.
The Jury's basis for their decision
We are immensely proud and thrilled to have won the Techarenan Challenge 2023 Business Award - and what a memorable event! This recognition is truly a testament to the relentless efforts of our exceptional, multidisciplinary team, whose contributions have all been integral in developing Dermalyser - our user-friendly, AI-based decision support tool that is revolutionizing the speed and accuracy of skin cancer diagnosis. We'd also like to extend our gratitude to the panel of judges and our congratulations to the winners in the other categories. Work now continues to bring Dermalyser as quickly as possible to market. Following our first clinical trial conducted at 37 Swedish primary care facilities with highly promising results, we now look forward to finalising the CE marking and preparing for market launch in Europe in 2024 and to engage US-based clinics in upcoming clinical trials as part of our US market entry strategy
Christopher Ekström, CEO of AI Medical Technology
This year’s list of finalists is one of the strongest and most versatile line-ups we’ve had so far at Techarenan Challenge. It’s impressive to see how entrepreneurs in various fields have, or are about to, change their respective industries, create new standards and improve society. I’m very much looking forward to following their journey in the coming years
Techarenan CEO and Founder Omid Ekhlasi
Analyzing membrane proteins using SPR can pose a challenge due to the inherent instability of these drug targets and the difficulty in immobilizing enough functional membrane protein on the biosensor surface to ensure a measurable binding signal. By employing this innovative technique, we were able to confirm target engagement and measure the binding affinities of various pharmacological agents that are known to inhibit PANX1 activity.
Stefan Geschwindner, Director of Biophysics, AstraZeneca
These results provide the basis for further investigations of novel PANX1 binders, leading to the development of more potent and specific compounds to further probe the biology of PANX1 and its potential as a therapeutic target. The novel methodology presented here accelerates the purification of membrane proteins that are ready to generate high-resolution cryo-EM structures, without the need for laborious and time-consuming detergent screenings, protein engineering or inefficient screening of alternative scaffolding setups.
Robin Löving, CSO of Salipro Biotech
We are excited to see the synergies of our collaboration come together, enabling the first structure-function studies of this drug target and laying the groundwork for future investigations of novel PANX1 binders. Once again we demonstrate that combining the strengths of complementary technologies indeed streamlines the process of discovering new therapeutic ligands and accelerates the development of new drugs.
Jens Frauenfeld, CEO of Salipro Biotech
The 12-week izokibep results, including 33% of patients achieving HiSCR100, are unparalleled for moderate-to-severe hidradenitis suppurativa patients compared to historical studies. We believe that the collective data for izokibep in psoriatic arthritis and hidradenitis suppurative demonstrate the potential of Affibody® molecules such as izokibep to deliver differentiated clinically meaningful benefit for patients.
Nikolai Brun, CMO of Affibody
These results suggest that GAGomes measured in the blood or urine could help clinicians understand if a patient with mRCC is responding or will respond to treatment. No liquid biomarkers are approved in metastatic renal cell carcinoma (mRCC). However, the number of treatments available today for mRCC has drastically increased in the last two decades. Therefore, there is a substantial need to predict and monitor response non-invasively to tailor treatment choices. These results are encouraging and raise tantalizing questions about the fundamental biology of mRCC considering the changes we observed in GAGomes when mRCC responds or does not respond to treatment. For clinical practice, however, we need independent studies to validate the use of GAGomes for monitoring mRCC patients.
Francesco Gatto, Affiliated Researcher at the Karolinska Institute and lead author of the study, as well as Co-Founder & CSO at Elypta.
This study adds further insights when it comes to the potential of using GAGomes to guide critical medical decisions in cancer. We now look forward to the results of our ongoing study for renal cell carcinoma recurrence surveillance to further validate the diagnostic and monitoring performance of GAGomes in renal cell carcinoma.
Karl Bergman, CEO at Elypta
This collaboration with Chiesi accelerates Affibody’s strategic development and further reinforces the competitiveness of our technology which has now been validated both clinically and commercially. We acknowledge and appreciate Chiesi’s significant commitment and expertise in the development of inhaled drugs and believe that this partnership will help maximize the value of inhaled Affibody ® molecules.
David Bejker, CEO of Affibody AB
Chiesi is committed to the research, discovery and development of novel innovative treatments in the respiratory diseases area which is a strategic priority for our organization. Our collaboration with Affibody adds an important new modality to our R&D portfolio that has particularly interesting properties for inhalation, and we look forward to developing new treatments for people with unmet medical needs based on this partnership.
Thomas Eichholtz, Head of Global Research and Development at Chiesi Group.
Today, we are delighted to be able to report Dermalyser's outstanding performance as a support tool for diagnosing melanoma skin cancer. The remarkably high sensitivity and specificity levels demonstrate the clinical performance and benefit of Dermalyser, particularly since the study was conducted in a real world, primary care setting representing different demographics, personnel, and geographical location. We now look forward to finalising the CE marking and preparing for market launch in Europe in Q4, 2023. Simultaneously, we plan to engage US-based clinics in upcoming clinical trials as part of our US market entry strategy.
Christoffer Ekström, CEO of AI Medical Technology
Indeed exciting results, these numbers show potential of not only improving future visual diagnostic accuracy, but also decreasing the amount of workload that dermatologist too often are dealing with in their daily practice. Nevertheless, additional studies are necessary to confirm the positive results. Human–computer collaboration is here to stay and I’m looking forward to its implementation in the field of skin cancer and dermatology in general.
Olle Larkö, Professor in Dermatology & Venereology and former Dean at Sahlgrenska University
In addition to the primary objective, i.e., the diagnostic precision of the device, we also determined the usability and applicability of Dermalyser in clinical practice. Results from the study will be reported in a clinical publication, but already the clear impression is a high acceptance of Dermalyser as a diagnostic support tool among the medical personnel involved.
Magnus Falk, Associate Professor in General Practice and Principal Investigator, Department of Health, Medicine and Caring Sciences, Linköping University.
There is a large unmet need for durable and efficient treatments for type 2 diabetes patients. We believe that our first-in-class drug candidate ATR-258 with its unique mode of action, has the potential to not only help these patients manage their blood glucose levels, but also help treat the actual cause of the disease. As of yet, no other type 2 diabetes drug has managed to achieve this.
Alexandra Ekman Ryding, Ph.D., CEO
We are delighted to close this round which will help us advance to the next stage in our journey to provide dermatologists and physicians with an accurate and reliable decision support tool to ensure rapid and accurate melanoma diagnosis. The extremely encouraging results from our recently completed multi-centre prospective clinical investigation involving 37 Swedish primary care facilities will be available shortly. The reaction from the Nordic dermatology community has already been so positive that we are responding to their request to run additional trials. This also has the additional benefit of further building our already market-leading image library. Combined, the new funds and trial results will enable us to accelerate our commercialisation program, starting with CE marking and launching in key European markets. FDA approval is also on the horizon, with this key market continuing to grow. However, forecasts also predict skin cancer to be an increasing problem in Latin America and Southeast Asia over the next decade.
AI Medical Technologies CEO Christoffer Ekström
AI-Medical Technology meets all of our criteria for investment – disruptive technology, a major unmet need and scalability in the key US market. We were also impressed by the ambition and drive of Christoffer and his team and look forward to supporting them in their mission to provide healthcare professionals with this invaluable new aid to diagnosis of skin cancer.
Henrik Jerner of Northern CapSek Ventures

Subscribe